Drug Trial Radar · NCT06278389
Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jan 24, 2024
Primary completion
May 20, 2024
Study completion May 20, 2024
Sponsor
- Lead sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Chengdu Aidea Pharmaceutical Technology Co., Ltd
- First posted
- Feb 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this clinical trial is to investigate the safety and tolerability of single ascending dose ACC017 tablets in Chinese healthy adult participants. This study aims to address the following major questions: * Recommended dosage for ACC017 tablets used in phase Ib/IIa trial; * The pharmacokinetic (PK) characteristics of single dose ACC017 tablets; * The effect of food (FE) on the PK of ACC017 tablets; * Drug-drug interactions (DDIs) when ACC017 tablets are co-administered with emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) tablets (II).
Conditions
- Healthy Adult Participants
Interventions
ACC017 tabletsDrug
ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo
Emtricitabine and Tenofovir Alafenamide Fumarate TabletsDrug
Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency, causality, severity, and expectedness of adverse events (AEs)Time frame: Day 1 through Day 8 of Stage 1; Day 1 through Day 8 and Day 15 through Day 22 of Stage 2
- ACC017 PK parameter: Cmax (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: C24h (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: AUC0-t (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: AUC0-∞ (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: Tmax (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: t1/2 (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: Vz/F (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: CL/F (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: λz (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: AUC_%Extrap (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: MRT0-t (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
- ACC017 PK parameter: MRT0-∞ (after a single mono-drug administration under the fasting condition)Time frame: Day 1 through Day 8 of Stage 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.